Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial

Key Points

• Tenecteplase demonstrates improved outcomes in patients with basilar artery occlusion.
• The trial shows a significant reduction in disability measured by the modified Rankin Scale at 90 days.
• This study employs a multicentre, prospective, randomized, open-label design with blinded endpoints.
• These findings may influence treatment protocols for acute basilar artery occlusion to integrate tenecteplase.